Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.
Bayer: Turnaround Is Underway - Don't Miss It
Bayer remains a 'Buy' as litigation overhangs ease and intrinsic value points to deep undervaluation. Despite disappointing 2025 results, Bayer's core business shows resilience, with litigation settlements expected to unlock higher free cash flow post-2026. Management forecasts mid-single-digit pharmaceutical growth from 2027, with Crop Science margins and free cash flow set to improve by 2029.
BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD
Bayer's finerenone hits key phase III goal in non-diabetic CKD, paving the way to expand Kerendia???s use as data strengthens its cardiorenal therapy role.
Bayer takes its multi-front battle on pesticide liability to Kansas
Kansas lawmakers were set to take up a bill on Tuesday backed by Bayer that would prevent people from suing pesticide manufacturers for not warning them that their products could cause cancer or other illnesses, as the German company readies a potential $7 billion-plus settlement for thousands of lawsuits over the weedkiller Roundup.
Bayer Advances Roundup Settlement With Missouri Court Approval
BAYRY wins preliminary court approval for a proposed Roundup class settlement, a key step in managing long-running glyphosate litigation and future liabilities.
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
Bayer's $7.25 billion Roundup settlement gets initial OK from Missouri judge
A state court judge in Missouri gave an initial green light on Wednesday to a proposed $7.25 billion settlement to resolve thousands of lawsuits claiming Bayer's Roundup weedkiller causes cancer.
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
BAYRY posts in-line Q4 earnings but revenues miss on lower Xarelto and Eylea sales. 2026 sales guidance signals steady growth ahead.
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Bayer proposes $7.25 billion Roundup settlement as Supreme Court case looms
A new $7.25 billion settlement between Bayer and a group of cancer patients could wrap up a huge wave of lawsuits against the company over allegations that it didn't warn consumers about cancer risks associated with the weedkiller Roundup.
